Effects of Chuanxiongqin hydrochloride on increasing the fluidity of brain cell membrane and scavenging free radicals in model rats with ischemia/reperfusion injury

BACKGROUND: The fluidity of cell membrane can be affected by various factors. Many experiments have confirmed that the ischemia/reperfusion of organic tissue can increase the contents of free radicals, which lead to high rigidity and low fluidity of cell membrane, and the conditions can be changed by Chuanxiongqin. OBJECTIVE: To observe the effect and mechanism of Chuanxiongqin hydrochloride on the fluidity of brain cell membrane in rat models of ischemia/reperfusion. DESIGN: A completely randomized controlled animal trial. SETTINGS: Institute of Brain Sciences; Department of Physiology, Medical College, Datong University. MATERIALS: Twenty male grade Ⅰ Wistar rats of 170-220 g were randomly divided into model group (n =10) and control group (n =10). Chuanxiongqin hydrochloride (molecular mass was 172.2) was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (batch number: 0817-9803); Spin labelers: 5-doxyl-stearlic acid methylester (5DS), 16-doxyl-stearlic acid methylester (16DS), xanthine, xanthine oxidase (XOD) and 5,5-dimeth-1-pyrroline- N-oxide (DMPO) from Sigma Company; Bruker ESP 300 electron paramagnetic resonance (EPR) spectrometer by Bruker Company (Germany). METHODS: The experiments were carried out in the State Key Laboratory of Natural and Biomimetic Drugs, Peking University from June 2001 to July 2002. In the model group, rats were made into models of cerebral ischemia by 30-minute ligation and 2-hour reperfusion of common carotid arteries; The rats in the control group were not made into models. The order parameter (S) and rotational correlation time (τc) were detected with the ESR spectrometer by means of spin labeling. The greater the S and τc, the smaller the fluidity. Meanwhile, the clearance rate of free radicals was detected with ESR spin trapping. The measurement data were compared using the t test. MAIN OUTCOME MEASURES: The S, τc and clearance rates of O2 · and OH· free radicals were compared between the model group and control group. RESULTS: The S and τc in the model group [0.738 4±0.003 5; (8.472±0.027)×10-10 s/circle] were obviously different from those in the control group [0.683 9±0.008 3; (7.945±0.082)×10-10 s/circle, t =5.731, 5.918, P < 0.05], which suggested that ischemia/reperfusion injury decreased the fluidity of brain cell membrane. After adding Chuanxiongqin hydrochloride, there were no obvious differences between the model group [0.688 5±0.030 5; (7.886±0.341)×10-10 s/circle] and control group (P > 0.05), indicating that Chuanxiongqin hydrochloride could recover the fluidity of brain cell membrane after ischemia/reperfusion injury close to the level in the normal control group. Chuanxiongqin hydrochloride could directly scavenge the O2 · and OH· free radicals, and the maximal clearance rates were 83.92% and 44.99% respectively. CONCLUSION: Chuanxiongqin hydrochloride increases the fluidity of membrane of ischemia-injured brain cell by scavenging both O2 ·and OH· free radicals.

Effects of Danshen Chuanxiongqin therapy on TXA2/PGI2, bone metabolism and stress levels after proximal femoral fracture surgery

Objective:To study the effects of Danshen Chuanxiongqin therapy on TXA2/PGI2, bone metabolism and stress levels after proximal femoral fracture surgery.Methods:A total of 80 patients with proximal femoral fractures who received open reduction and internal fixation treatment in the First Affiliated Hospital of the Fourth Military Medical University between January 2015 and December 2016 were selected as the research subjects and randomly divided into the experimental group who received postoperative adjuvant Danshen Chuanxiongqin therapy and the control group who received postoperative conventional therapy. The levels of TXA2/PGI2 balance-related indicators, bone metabolism indicators and stress hormones in serum as well as the expression levels of stress molecules in peripheral blood were measured before surgery and 3 d after surgery.Results:Compared with those of same group before surgery, serum 6-keto-PGF1α, t-PA, PICP, BALP and OCN levels of both groups of patients were significantly lower whereas serum TXB2, PAI-1, D-D,β-CTX, RANKL, NE, COR and ANG-Ⅱ levels as well as peripheral blood NF-κB and HSP70 expression were significantly higher after surgery, and serum 6-keto-PGF1α, t-PA, PICP, BALP and OCN levels of experimental group after surgery were higher than those of control group whereas serum TXB2, PAI-1, D-D,β-CTX, RANKL, NE, COR and ANG-Ⅱ levels as well as peripheral blood NF-κB and HSP70 expression were lower than those of control group.Conclusion:Danshen Chuanxiongqin therapy after proximal femoral fracture surgery can adjust the TXA2/PGI2 balance, improve the bone metabolism and reduce the stress level.

Complex Drug Network of Danshen Chuanxiongqin Injection(丹参川芎嗪注射液)Treatment for Liver Insufficiency

Objective:To study the characteristics and rules of medication regimen for patients with Liver insufficiency treated with Danshen Chuanxiongqin Injection.Methods:The inpatient information of Danshen Chuanxiongqin Injection with Liver insufficiency was extracted from the hospital information system(HIS)database of 12 Class A tertiary hospitals in China.Tabu search(TS)algorithm was used for obtaining sub-network and density matrix,matrix method or sociogram was used to show the relationship between different sub-networks,searching for core prescriptions of treatment options,associations and strong correlations between multiple drugs.Results:The treatment plan of integrated Chinese and Western medicine of Danshen Chuanxiongqin Injection on Liver insufficiency mainly includes of cerebrovascular disease in acute stress state:Danshen Chuanxiongqin Injection combined with alanyl glutamine;Treatment of acute ischemic cardiovascular and cerebrovascular diseases:Danshen Chuanxiongqin Injection combined with Levocarnitine+acetylsalicylic acid+inosine tablets+brain protein hydrolysate+glutathione+furosemide+Magnesium aspartate+metoprolol;Treatment of ischemic cardiomyopathy angina pectoris with traditional Chinese medicine:Danshen Chuanxiongqin Injection combined with Shexiang Baoxin Pills+Suxiao Jiuxin Pills+Fufang Danshen Drops;Treatment of ischemic cardiovascular disease complicated with Liver insufficiency with traditional Chinese medicine:Danshen Chuanxiongqin Injection combined with Dazhu Hongjingtian Capsule+Shuganning Injection.Conclusion:For Danshen Chuanxiongqin Injection in patients with Liver insufficiency,on the basis of conventional symptomatic treatment,attention should be paid to the liver function of the patients,integrated therapy can be more selective,can improve the efficacy in different degrees.Danshen Chuanxiongqin Injection combination scheme of Liver insufficiency in routine clinical diagnosis and treatment provides a more effective reference for clinical individualized treatment.

丹参川芎嗪注射液联合曲美他嗪对不稳定型心绞痛患者心电图、心功能的影响

【目的】探讨丹参川芎嗪注射液联合曲美他嗪对不稳定型心绞痛(UAP)患者心电图、心功能的影响。【方法】回顾性分析2021年1月至2023年5月本院收治的106例UAP患者的临床资料,根据治疗方法的不同将其分为对照组和观察组,每组53例。对照组采用曲美他嗪治疗,观察组采用丹参川芎嗪注射液+曲美他嗪治疗。比较两组临床疗效、发作频率、硝酸甘油用量、持续时间、心功能指标[心排血量(CO)、左心室射血分数(LVEF)、每搏输出量(SV)]、心电图变化情况[ST段压低幅度、ST段压低次数]、血清生化指标[血管生成素样蛋白2(Angptls2)、氧化型低密度脂蛋白(ox-LDL)、C1q肿瘤坏死因子相关蛋白1(CTRP1)]及不良反应发生情况。【结果】观察组有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组发作频率、硝酸甘油用量、持续时间少于治疗前,且观察组少于对照组(P<0.05);两组CO、LVEF、SV均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组ST段压低幅度、ST段压低次数均低于治疗前,且观察组低于对照组(P<0.05);两组血清Angptls2、ox-LDL、CTRP1水平低于治疗前,且观察组低于对照组(P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。【结论】丹参川芎嗪注射液联合曲美他嗪治疗UAP临床疗效较好,有助于减轻患者症状,改善心功能,安全性高。

丹参川芎嗪注射液治疗冠心病心绞痛系统评价

目的系统评价丹参川芎嗪注射液用于治疗冠心病心绞痛的有效性及安全性。方法全面系统地检索中国知识资源总库(CNKI)、中文科技期刊数据库(VIP)、中国学术期刊数据库(万方数据)、中国生物医学文献数据库(CBM)、Pub Med、Embase和Cochrane Library等数据库,检索时间2014年2月,获得符合纳入标准的随机及半随机临床对照试验。2名研究者独立采用Cochrane风险评价表评价其研究质量,并提取所需资料,采用Rev Man5.2软件进行Meta分析。结果共纳入12篇文献,共计受试者1145例。Meta分析结果显示,丹参川芎嗪注射液联合西医常规疗法治疗冠心病心绞痛具有较好疗效,临床总有效率[RR=1.27,95%CI(1.19,1.35),P<0.000 01]、改善心电图总有效率[RR=1.34,95%CI(1.23,1.46),P<0.000 01]优于对照组,且能更好地降低血浆黏度[MD=-0.15,95%CI(-0.25,-0.05),P=0.004]、纤维蛋白原[MD=-0.96,95%CI(-1.14,-0.78),P<0.000 01]等。临床未见不良反应报告。结论丹参川芎嗪注射液用于治疗冠心病心绞痛具有一定的疗效且相对安全,但仍需进行大样本、多中心、高质量的临床随机对照试验进一步验证。

丹参川芎嗪注射液对不稳定型心绞痛患者冠脉介入术后心肌损伤的影响

目的观察丹参川芎嗪注射液对不稳定型心绞痛(unstable angina,UA)患者经皮冠状动脉介入术(percutaneous coronary intervention,PCI)治疗后心肌损伤的影响。方法将76例UA患者随机分为试验组(39例)和对照组(37例)。两组均给予西药常规治疗及PCI手术治疗,试验组在常规治疗基础上于PCI术前3～5天给予丹参川芎嗪注射液10mL加入250mL生理盐水中静脉滴注,每天1次,共7～10天。观察两组患者用药前后血小板P-选择素阳性表达的变化,PCI术后心肌梗死溶栓试验(thrombolysis in myocardial infarction,TIMI)心肌灌注(myocardial perfusion,TMP)分数及心肌损伤标志物肌酸激酶同工酶(CK-MB)和肌钙蛋白I(TnI)的水平。结果用药后试验组P-选择素阳性表达率[(2·45±1·42)%]低于同期对照组[(4·43±1·79)%],差异有统计学意义(P<0·05)。PCI术后试验组TMP0/1级的发生率及CK-MB、TnI水平低于同期对照组,差异有统计学意义(P<0·05)。两组住院期间均无心脏事件发生。结论 PCI术前给予丹参川芎嗪注射液能够有效抑制血小板的激活,改善术后心肌血流灌注,降低心肌损伤的发生。

丹参川芎嗪注射液联合神经节苷脂对急性重度一氧化碳中毒患者乳酸清除率及预后的影响

目的探讨丹参川芎嗪注射液联合神经节苷脂对急性重度一氧化碳中毒(ASCOP)患者的疗效。方法选取2011年1月-2015年3月该院ASCOP患者329例,随机分成对照组(A组)、丹参川芎嗪注射液组(B组)、神经节苷脂组(C组)和丹参川芎嗪注射液联合神经节苷脂治疗组(D组),A组给予高压氧、防治脑水肿及促进脑细胞代谢等治疗;B组在常规治疗基础上加用丹参川芎嗪注射液;C组在常规治疗基础上加用神经节苷脂;D组在常规治疗基础上加用丹参川芎嗪注射液和神经节苷脂联合治疗。4组均2周为1个疗程。所有患者均于治疗前及治疗后6、24和72 h在不吸氧条件下取1 ml动脉血,检测动脉血乳酸,同时计算LCR。比较4组患者的初始血乳酸水平及6、24和72 h LCR。观察4组患者急性生理学和慢性健康状况Ⅱ(APACHEⅡ)评分、治疗2周后的临床症状改善情况、急性一氧化碳中毒迟发性脑病的发生率及病死率。结果 D组的总有效率高于A、B、C组,差异有统计学意义;4组患者入院时乳酸水平和APACHEⅡ评分比较差异无统计学意义;治疗后D组患者6和24 h LCR明显高于A、B、C组;B组与A组、C组与A组比较,差异有统计学意义(P<0.05),B组与C组比较差异无统计学意义(P>0.05);治疗后D组患者6、24和72 h急性生理学和APACHE状况Ⅱ评分低于A、B、C组,B组与A组、C组与A组比较,差异有统计学意义(P<0.05),B组与C组比较差异无统计学意义(P>0.05);治疗72 h后4组的LCR比较差异无统计学意义(P>0.05);治疗后D组患者急性一氧化碳中毒迟发性脑病的发生率和患者病死率低于A、B、C组,B组与A组、C组与A组、B组与C组比较差异无统计学意义(P>0.05)。结论丹参川芎嗪联合神经节苷脂治疗ASCOP患者能有效地提高LCR,降低急性生理学和APACHEⅡ评分,减少急性一氧化碳中毒迟发性脑病的发生率和病死率,改善患者预后,临床疗效显著,值得推广应用。

丹参川芎嗪注射液联合高压氧对急性脊髓损伤早期并发症的预防作用

目的:探讨丹参川芎嗪注射液联合高压氧对急性脊髓损伤早期并发症的预防作用。方法:按随机数字表法将89例急性脊髓损伤患者分为对照组(n=44)和联合组(n=45)两组。对照组予以常规对症治疗联合高压氧疗法;联合组在对照组治疗基础上给予丹参川芎嗪注射液10 mL加入250 mL 0.9%氯化钠注射液中静脉滴注,bid。两组患者均治疗2周。比较两组患者治疗前后脊柱功能恢复指标(Botsford、FIM评分)、凝血指标[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)]、血液流变学指标(全血高切黏度、血浆黏度、红细胞聚集指数)及炎症指标[D-二聚体(D-D)、C反应蛋白(CRP)];随访1个月,比较两组患者深静脉血栓、肺动脉栓塞等早期并发症发生率。结果:对照组中途脱落2例,联合组中途脱落3例,两组各有42例患者入组。治疗前,两组患者各项指标比较,差异均无统计学意义(P>0.05)。治疗2周后,两组患者Botsford、FIM评分均较治疗前显著提升,PT、APTT均较治疗前显著增加,全血高切黏度、血浆黏度、红细胞聚集指数及D-D、CRP水平均较治疗前显著降低,且联合组各指标均显著优于对照组,差异均有统计学意义(P<0.05或P<0.01)。联合组患者早期并发症发生率为16.7%,显著低于对照组的35.7%,差异有统计学意义(P<0.05)。结论:将丹参川芎嗪注射液联合高压氧应用于急性脊髓损伤患者外科手术后,可有效降低其深静脉血栓、肺动脉栓塞等早期并发症发生风险,对缓解炎症反应、促进血液微循环、改善患者预后等有积极作用。

静脉用川芎嗪与维生素C配伍微粒实验

采用天津天河医疗仪器研制中心生产的ＺＷＦ－４Ｃ注射液微粒分析仪对川芎嗪与维生素Ｃ分别及混合加入５％ＧＳ液内进行液体微粒检测，目的是指导临床护士采用正确加药方式，确保液体质量及疗效。通过检测提示川芎嗪与极化液作为一组液体输液时，应将川芎嗪与极化液分别加入５％ＧＳ液体内，以免发生不良反应。

参芎嗪注射液对大鼠脑缺血损伤血液流变学、脑含水量的影响

目的复制脑缺血大鼠模型,研究参芎嗪注射液对实验性脑缺血大鼠的干预作用。方法通过线栓法复制大鼠脑缺血模型,设立假手术组、模型组、川芎嗪注射液组、参芎嗪注射液组,观察各组治疗前后血液流变学、脑含水量、脑指数的影响。结果参芎嗪注射液可改善血液流变学,降低脑含水量及脑指数,与模型组比较差异有统计学意义(P<0.05或P<0.01)。结论参芎嗪注射液可改善微循环、减轻脑水肿,对脑缺血损伤起到较好的保护作用。

丹参川芎嗪注射液对急性脑梗死老年患者血清血管细胞间黏附分子-1、细胞间黏附分子-1、内皮素-1和一氧化氮水平的影响

目的观察丹参川芎嗪注射液对急性脑梗死老年患者血清血管细胞间黏附分子-1(VCAM-1)、细胞间黏附分子-1(ICAM-1)、内皮素-1(ET-1)和一氧化氮(NO)水平的影响。方法将168例急性脑梗死老年患者随机分为2组,对照组84例给予常规内科治疗,观察组84例在对照组治疗基础上加用丹参川芎嗪注射液治疗;比较2组临床效果以及治疗前后VCAM-1、ICAM-1、ET-1与NO水平。结果治疗2周后,观察组临床总有效率明显高于对照组(P<0.05),神经功能缺损程度评分、Barthel指数显著优于对照组(P均<0.05),血清VCAM-1、ICAM-1、ET-1、NO水平下降幅度均显著高于对照组(P均<0.05);2组均未见严重不良反应。结论丹参川芎嗪注射液治疗老年急性脑梗死的临床疗效确切,能够有效降低患者血清VCAM-1、ICAM-1、ET-1、NO水平,用药安全性高,具有较高的临床应用价值。

丹参川芎嗪注射液中丹参素钠和原儿茶醛的含量测定及不确定度评定

目的建立测定丹参川芎嗪注射液中丹参素钠和原儿茶醛含量的方法,并对测量结果进行不确定度评定。方法采用高效液相色谱法,以甲醇-0.2%冰醋酸为流动相,检测波长为280 nm,分析测定过程和步骤,量化具体的不确定度分量。结果丹参川芎嗪注射液中丹参素钠含量为(0.4384±0.0026)mg·m L-1,原儿茶醛的含量为(0.0740±0.0006)mg·m L-1,对照品称量、稀释过程和方法准确度对合成不确定度的贡献较大。结论测量不确定度的评价为丹参川芎嗪注射液中丹参素钠和原儿茶醛含量测定的可信度提供一种数学判断方法,对其质量控制具有指导意义。

丹参川芎嗪治疗早期糖尿病肾病临床效果及对炎性因子影响

目的探讨丹参川穹嗪对早期糖尿病肾病的临床治疗效果及对患者体内炎性因子的影响.方法选取87例早期糖尿病肾病患者为研究对象,将其按照不同治疗方法分为对照组和研究组,对照组44例,采用常规方法治疗;研究组43例,在对照组基础上添加丹参川穹嗪进行治疗,观察两组患者治疗的总有效率及不良反应发生率,并将两组患者的UAER,UACR,β2-MG及血清IL-6,IL-18,TNF-α进行观察和比较.结果对照组患者总有效率及不良反应发生率分别为78.57%和23.81%;治疗后UAER,UACR,β2-MG分别为(110.31±19.27)mg/d,(81.46±9.46)mg/g,(17.69±4.68)mg/L;血清IL-6,IL-18,TNF-α分别为(12.13±2.10),(135.21±37.23),(39.21±11.25)mg/L.研究组患者总有效率及不良反应发生率分别为95.12%,4.88%;治疗后UAER,UACR,β2-MG分别为(92.16±21.39)mg/d,(67.14±8.15)mg/g,(13.62±4.21)mg/L;血清IL-6,IL-18,TNF-α分别为(8.05±2.01),(103.26±32.85),(23.68±11.84)mg/L.两组间各数据比较差异具有统计学意义(P<0.05).结论丹参川穹嗪在早期糖尿病肾病的治疗中能够有效降低患者体内炎性因子水平.

丹参川芎嗪联合长春西汀治疗颅脑损伤后遗症的临床研究

目的探讨丹参川芎嗪联合长春西汀治疗脑损伤后遗症的临床疗效。方法选择我院收治的颅脑损伤后遗症患者80例为研究对象,随机分为两组,每组40例,对照组患者予能量合剂+高压氧治疗,观察组予丹参川芎嗪注射液+长春西汀注射液治疗,观察两组患者临床疗效及治疗后血液流变学指标的变化。结果观察组患者治疗总有效率为92.5%,明显高于对照组的75.0%,差异有统计学意义(P<0.05);观察组患者治疗后全血比粘度(高切、中切、低切)、血浆粘度、红细胞压积、纤维蛋白原以及血清hs-CRP均较治疗前明显降低,且明显低于对照组水平,差异有统计学意义(P<0.05);对照组治疗后上述指标与治疗前比较均无统计学差异(P>0.05)。结论丹参川芎嗪联合长春西汀治疗脑损伤后遗症可有效减轻炎症反应,改善患者的血液高粘滞状态,进而增加脑血流量,提高临床疗效。

丹参川芎嗪注射液联合常规治疗对脑卒中患者血液流变的影响

目的:探讨丹参川芎嗪注射液联合常规治疗对脑卒中患者血液流变学的影响。方法:将我院2010年12月至2011年5月收治的100例脑卒中的患者按照治疗方法的不同分为治疗组和对照组,对照组采用脑卒中常规疗法,治疗组在对照组的基础上采用丹参注射液治疗,比较两组患者的治疗效果及血液流变学的变化。结果:两组患者均无恶化和死亡病例出现,治疗组的总有效率为72.0%显著高于对照组的52.0%(P<0.05)。观察组的全血高切粘度、全血低切粘度以及红细胞压积改善显著优于对照组(P<0.05)。结论:丹参川芎嗪注射液联合常规治疗能显著提高脑卒中患者的治疗效果,可能与其减低患者的血液粘度,增加脑部血液供应有关。

丹参川芎嗪注射液对老年顽固性心力衰竭合并低血压患者心肾功能的改善作用

目的探讨丹参川芎嗪注射液对老年顽固性心力衰竭合并低血压患者心肾功能的改善作用。方法选取老年顽固性心力衰竭合并低血压患者共100例,按随机数字表法分为观察组和对照组各50例。在常规治疗的基础上,对照组给予多巴胺联合多巴酚丁胺治疗,观察组给予丹参川芎嗪注射液治疗。比较两组患者治疗前后SBP、DBP、心率、血浆肾素活性、血管紧张素Ⅱ、醛固酮、血清肌酐(SCr)、左心室射血分数(LVEF)、每搏输出量(SV)、N末端前体脑钠肽(NT-proBNP)及估算肾小球滤过率(e GFR)。结果与治疗前比较,治疗后两组SBP、DBP、SV、LVEF、eGFR均增高,血浆肾素活性、血管紧张素Ⅱ、Nt-proBNP、SCr水平均降低(P<0.05),观察组心率及醛固酮水平均降低,对照组醛固酮水平升高(P<0.05)。治疗后观察组心率、血浆肾素活性、血管紧张素Ⅱ、醛固酮、Nt-proBNP、SCr均低于对照组,SV、LVEF、eGFR均高于对照组(P<0.05)。结论丹参川芎嗪注射液可有效改善老年顽固性心力衰竭合并低血压患者的心肾功能。

川芎嗪注射液对实验性屈肌腱粘连的影响

本实验观察了川芎嗪注射液对鸡屈深肌腱粘连模型的影响，并与具有抗组织粘连作用的二甲基硅油及生理盐水进行对照。结果显示：川芎嗪与硅油组的损伤肌腱滑动功能好且粘连面积小，与盐水组比较有显著性差异（Ｐ＜０．０５，Ｐ＜０．０１）。而在肌腱的修复方面，川芎嗪又明显优于硅油组。表明：在损伤肌腱的鞘管内局部运用川芎嗪注射液既可减轻其腱周粘连，又不影响肌腱自身的愈合过程。

人参川芎嗪注射液对局灶性脑缺血大鼠血浆t-PA含量及活性、PAI-1含量、脑组织形态学的影响

目的:复制局灶性脑缺血大鼠模型,研究人参川芎嗪注射液对局灶性脑缺血大鼠血浆纤溶指标及脑组织形态学的影响。方法:通过电凝大脑中动脉复制大鼠脑缺血模型,设立假手术组、模型组、川芎嗪注射液组、人参川芎嗪注射液组,观察大鼠脑梗死后的血浆纤溶指标,光镜下观察脑组织形态。结果:人参川芎嗪注射液能显著提高局灶性脑缺血大鼠血浆组织型纤溶酶原激活剂(tissue-type plasminogen activator,t-PA)含量及活性,降低脑缺血纤溶酶原激活物抑制剂-1(plas-minogen activator inhibitor-1,PAI-1)含量,效果优于川芎嗪。结论:人参川芎嗪注射液通过提高血浆t-PA含量及活性,降低PAI-1含量对局灶性脑缺血损伤起到良好的干预作用,优于临床川芎嗪注射液。

丹参川芎嗪注射液联合神经节苷脂治疗一氧化碳中毒后患者脑氧利用率的变化及意义

目的观察急性一氧化碳中毒（ACOP）患者应用丹参川芎嗪注射液联合神经节苷脂治疗后脑氧利用率（O2UCc）的变化及意义。方法采用前瞻性研究方法，选择2011年1月至2016年1月入住河北医科大学附属哈励逊国际和平医院急救医学部的206例ACOP患者，按随机数字表法分为丹参川芎嗪组、神经节苷脂组和丹参川芎嗪注射液联合神经节苷脂治疗组（联合治疗组）。所有患者均于治疗前及治疗后6h、1d、3d经颈内动脉和颈内静脉采血，检测颈内动脉血氧饱和度（SaO2）和颈内静脉血氧饱和度（SjO2），根据公式推导O2UCc[O2UCc=s（a—i）O2／SaO2]。比较3组患者治疗前后O2UCc的变化；观察治疗14d后患者临床症状改善情况、ACOP迟发性脑病（DEACMP）的发生率及28d病死率。结果联合治疗组总有效率明显高于丹参川芎嗪组和神经节苷脂组[91．67％（66／72）比77．27％（51／66）、77．94％（53／68），均P〈0．05]。3组患者治疗前O2UCc水平比较差异无统计学意义；治疗后6h和1d联合治疗组O，UCc均明显低于丹参川芎嗪注射液组和神经节苷脂组[6h：（38．13±7．95）％比（42．96±7．58）％、（42．30±9，87）％，1d：（28．42±5．41）％比（33．27±7．53）％、（32．64±6．76）％，均P〈0．05]，而丹参川芎嗪组、神经节苷脂组患者治疗6h和1d后O2UCc比较差异无统计学意义；治疗3d后丹参川芎嗪组、神经节苷脂组、联合治疗组O2UCc水平数值已接近[分别为（23．87±6．06）％、（22．38±6．09）％、（23．68±4．34）％，均P〉0．05]。联合治疗组DEACMP发生率和28d病死率均低于丹参川芎嗪组和神经节苷脂组[发生率：2．78％（2／72）比12．12％（8／66）、14．71％（10／68），28d病死率：2．78％（2／72）比13．64％（9／66）、16.18％（11／68），均JP〈0．05]，而丹参川芎嗪组与神经节苷脂组DEACMP发生率和28d病死率比较差异均无统计学意义（均P〉0．05）。3组均无不良反应发生。结论丹参川芎嗪联合神经节阡脂治疗ACOP患者能有效降低O2UCc水平和DEACMP的发生率以及28d病死率，改善患者预后，临床疗效良好。

川芎嗪注射液佐治慢性肺源性心脏病的临床研究

目的评价川芎嗪注射液配合西医常规治疗慢性肺源性心脏病的临床疗效及对血气分析、血液流变学、血管紧张素Ⅱ、肺动脉压力的影响,探讨活血化瘀法能否成为辅助治疗慢性肺源性心脏病的有效方法。方法随机将慢性肺源性心脏病患者60例分为对照组(予单纯西医治疗)和观察组(予川芎嗪注射液+西医治疗),治疗前后进行临床症状、体征评估和血气分析、血液流变学、血管紧张素Ⅱ、肺动脉压力检测。结果观察组的总体疗效和气短、尿少、水肿症状改善均优于对照组(P均<0.05),2组血液流变学指标、血气分析、血管紧张素Ⅱ水平以及肺动脉压力比较均有显著性差异(P均<0.05)。结论川芎嗪注射液配合西医常规治疗慢性肺源性心脏病疗效优于单纯西医治疗,为中西医结合治疗慢性肺源性心脏病提供了新的思路。